Arvinas, Inc. (ARVN)

31,60 -0,94 (-2,89%) Al cierre: 04:00PM EDT

Arvinas, Inc.

5 Science Park
395 Winchester Avenue
New Haven, CT 06511
United States
203 535 1456
https://www.arvinas.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 445

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. John G. Houston Ph.D.	Chairperson, CEO & President	1,14M	N/A	1960
Dr. Ian Taylor Ph.D.	Chief Scientific Officer	732,26k	N/A	1963
Dr. Randy Teel Ph.D.	Interim CFO & Treasurer	N/A	N/A	1980
Mr. David K. Loomis M.B.A.	VP & Chief Accounting Officer	N/A	N/A	1974
Mr. Jeff Boyle	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Jared M. Freedberg J.D.	General Counsel & Corporate Secretary	N/A	N/A	1969
Mr. Steve Weiss	Senior VP & Chief Human Resources Officer	N/A	N/A	1970
Dr. John A. Grosso Ph.D.	Senior Vice President of R&D Technical Operations	N/A	N/A	1957
Ms. Angela M. Cacace Ph.D.	Senior Vice President of Neuroscience & Platform Biology	N/A	N/A	1968
Mr. John P. Northcott	Chief Commercial Officer	N/A	N/A	1978

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Gobierno corporativo

El ISS Governance QualityScore de Arvinas, Inc., a día 1 de abril de 2024, es 8. Las puntuaciones base son Auditoría: 4; Tablero: 8; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.